Modigene Inc. (OTCBB: MODG) today announced the appointment of Phillip Frost, M.D., as Chairman of its Board of Directors. Modigene also announced the appointments of two new directors, Dr. Marian Gorecki and Steven D. Rubin, and the departures of current Board Chairman and director Dr. Eugene Bauer and current
director Joel Kanter.
Coronis Partners will sponsor the ILSI Biomed 7th annual meeting to be held on May 2008 and conduct its second annual meeting as a satellite symposia.
Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
The Laboratory-Developed Test is Designed to Differentiate Squamous From Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Classifying Squamous Cell Carcinoma of the Lung With Sensitivity of 96 Percent and Specificity of 90 Percent.
.gif)
The analyst's 12 month target price was set on $15.5, 50% higher than the previous target price.
Modigene Inc. (OTCBB: MODG) today announced the appointment of Phillip Frost, M.D., as Chairman of its Board of Directors. Modigene also announced the appointments of two new directors, Dr. Marian Gorecki and Steven D. Rubin, and the departures of current Board Chairman and director Dr. Eugene Bauer and current
director Joel Kanter..gif)
REGINA, SASKATCHEWAN, CANADA and REHOVOT, ISRAEL Viterra (TSX: VT) and Evogene Ltd. (TASE: EVGN) today announced a joint collaboration to develop canola with improved yield and tolerance to abiotic stress. Under the three year collaboration, the companies will assess a number of Evogene discovered gene candidates in trials involving Viterra's elite canola lines. These varieties will be evaluated under normal and stress conditions.
.gif){kind=logo}
Roth Capital Partners LLC initiating coverage of Modigene with a BUY rating and a 12-month price target of $2.50/share.
Salio, Inc., announced a collaboration and license agreement with Semorex, developer of Molecularly Imprinted Polymers. Semorex will license Salio’s Smart Materials for use with its proprietary Ergosterol sensing MIP technology. Salio and Semorex will collaborate in the preperation and testing of the Smart MIP, which is expected to be completed during 2008.
The company has announced the successful expression of two versions of its 2nd generation, Multimeric vaccine against influenza. After its purification, the company intends to examine this vaccine in animal models.
